Diabetes: metformin, SGLT2 inhibitors and semaglutide (T2DM and CVD)

  • In development GID-IND10348
  • Expected publication date: TBC

Register as a stakeholder

Status:
In progress
Process:
IND

Timeline

Key events during the development of the guidance:

DateUpdate
08 April 2026 - 06 May 2026NICE indicator consultation
08 April 2026Statement